LFM-A13

LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research[1][3][4]

Product Specifications

CAS Number

[62004-35-7]

UNSPSC

12352200

Hazard Statement

H302+H312+H332, H315, H319

Target

Btk; JAK; Polo-like Kinase (PLK)

Type

Biochemical Assay Reagents

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/lfm-a13-1.html

Purity

99.65

Solubility

10 mM in DMSO

Smiles

C/C(O)=C(C#N)/C(NC1=CC(Br)=CC=C1Br)=O

Molecular Formula

C11H8Br2N2O2

Molecular Weight

360.00

Precautions

H302+H312+H332, H315, H319

References & Citations

[1]Mahajan S, et al. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N- (2, 5-dibromophenyl) propenamide]. J Biol Chem. 1999 Apr 2;274 (14) :9587-99.|[2] van den Akker E, et al. The Btk inhibitor LFM-A13 is a potent inhibitor of Jak2 kinase activity. Biol Chem. 2004 May;385 (5) :409-13.|[3]Uckun FM, et al. Anti-breast cancer activity of LFM-A13, a potent inhibitor of Polo-like kinase (PLK) . Bioorg Med Chem. 2007 Jan 15;15 (2) :800-14.|[4]Sahin K, et al. LFM-A13, a potent inhibitor of polo-like kinase, inhibits breast carcinogenesis by suppressing proliferation activity and inducing apoptosis in breast tumors of mice. Invest New Drugs. 2018 Jun;36 (3) :388-395.